Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focusing on novel cancer therapies, has announced the granting of 17,000 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted on September 30, 2024, under the company's 2022 Inducement Stock Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).

The RSU awards will vest over a three-year period, with 33 1/3% of the shares vesting on each anniversary of the Grant Date, subject to continued employment. In the event of a "change in control event" followed by termination for "good reason" or without "cause" within one year, the RSUs will become immediately exercisable in full.

Positive

• Granting of RSUs to attract and retain new talent
• Alignment of employee interests with company performance through equity-based compensation

Negative

• None.

NEWTON, Mass., Oct. 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 17,000 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted as of September 30, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the applicable RSU agreement).

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first­in­class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex­U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302263260.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

How many restricted stock units (RSUs) did Karyopharm Therapeutics (KPTI) grant to new employees on September 30, 2024?

Karyopharm Therapeutics (KPTI) granted an aggregate of 17,000 restricted stock units (RSUs) to three newly-hired employees on September 30, 2024.

What is the vesting schedule for the RSUs granted by Karyopharm Therapeutics (KPTI)?

The RSUs granted by Karyopharm Therapeutics (KPTI) will vest over three years, with 33 1/3% of the shares vesting on each of the three consecutive anniversaries of the Grant Date.

Under what circumstances would the RSUs granted by Karyopharm Therapeutics (KPTI) become immediately exercisable?

The RSUs would become immediately exercisable if, within one year of a 'change in control event,' the employee's employment is terminated for 'good reason' by the employee or without 'cause' by Karyopharm Therapeutics (KPTI).

What Nasdaq rule did Karyopharm Therapeutics (KPTI) comply with when granting these RSUs?

Karyopharm Therapeutics (KPTI) granted these RSUs in compliance with Nasdaq Listing Rule 5635(c)(4), which allows for inducement grants to new employees.